Hong Kong drug regulator faces first real credibility test
SCMP · 1 SOURCESabout 4 hours ago2 MIN
Summary
Hong Kong has taken a concrete step in building its new medical products regulator by appointing Dr Li Zili as controller of the Hong Kong Centre for Medical Products Regulation. The appointment supports the government’s ambition to develop the city into a health and medical innovation hub, but the centre’s real test will be whether it can convert Hong Kong’s regulatory reputation and mainland industry links into a credible evaluation mechanism
Key Points
- Dr Li Zili was appointed controller of the Hong Kong Centre for Medical Products Regulation, removing one major item from the city’s biotech development to-do list
- Li is a mainland-born former senior official of the US Food and Drug Administration with 30 years of drug development and regulatory experience
- He said Hong Kong’s advantage rests on “one country, two systems” and the mainland’s strong pharmaceutical industry working in a mutually reinforcing relationship
- Li was educated at Peking Union Medical College and Johns Hopkins University, and also worked at several multinational drug companies
- Chinese innovative drug overseas licensing deals exceeded US$130 billion last year, while the mainland accounted for about one-third of the global active innovative drug pipeline
Why It Matters
If Hong Kong can build a trusted local evaluation mechanism, it could help mainland-developed drugs reach international markets while strengthening the city’s role beyond that of a simple intermediary. The challenge now is institutional: the new regulator must prove it can match Hong Kong’s high standards with timely, credible decisions that serve patients and the life sciences sector